Bionyra Pharma emerged from stealth after raising an oversubscribed $165 million Series A to develop next-generation biologics for severe immunological and inflammatory diseases. The clinical-stage startup is co-founded by Frédéric Marrache, MD, PhD, who built the company around target and pathway differentiation in immune-driven disorders. The round was co-led by Jeito Capital and Sofinnova Partners, with participation from Arkin Bio, Sanofi Ventures, Sixty Degree Capital, Vives Partners, and Apollo Health Ventures. Board additions include Jeito partner Mehdi Ainouche, Sofinnova partner Anta Gkelou, Arkin Bio principal Avital Adler, and Sanofi Ventures partner Laia Crespo. Bionyra’s financing signals continued appetite for early clinical biologics focused on pathway-level differentiation, particularly in areas where entrenched mechanisms and safety profiles demand careful target selection. The company framed its investor support as tied to Marrache’s immune and inflammatory disease expertise and the board’s experience in company building. For the sector, the launch underscores how large capital continues to flow into inflammation-first modalities even as regulatory scrutiny and pricing pressure shape later-stage risk calculations.